Icosapent Ethyl
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Icosapent ethyl is a highly purified ethyl ester of eicosapentaenoic acid (EPA) prescribed to lower very high triglycerides and to reduce the risk of cardiovascular events in selected patients already on statin therapy. Unlike combination fish oil products, it contains only EPA and no docosahexaenoic acid (DHA), which avoids the LDL-cholesterol increases sometimes seen with DHA-containing preparations. It is taken as oral capsules with food.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Icosapent ethyl is a highly purified ethyl ester of eicosapentaenoic acid (EPA) prescribed to lower very high triglycerides and to reduce the risk of cardiovascular events in selected patients already on statin therapy. NutriStack rates the supporting evidence as strong. Common adult dosing is 4 grams per day taken orally, given as either two 1-gram capsules twice daily or four 0.5-gram capsules twice daily, with food, though a prescriber sets the actual dose. This profile indexes 3 sources.
- Adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglycerides at or above 500 mg/dL)1,2
- Reduction of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, unstable angina) in statin-treated adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors1,3
The bottom line
Evidence rating strong. Most-documented uses: adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglycerides at or above 500 mg/dl), reduction of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, unstable angina) in statin-treated adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors. 3 sources indexed (2011–2019), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
The exact mechanism for triglyceride lowering is not fully established but is thought to involve reduced hepatic synthesis and secretion of very-low-density lipoprotein (VLDL) triglycerides and enhanced clearance of triglycerides from circulating VLDL particles. EPA may inhibit acyl-CoA:1,2-diacylglycerol acyltransferase, decrease hepatic lipogenesis, and increase fatty acid beta-oxidation. Beyond lipid effects, EPA is incorporated into cell membrane phospholipids where it modulates eicosanoid production, exerts anti-inflammatory and antithrombotic effects, may stabilize atherosclerotic plaque, and improves endothelial function, mechanisms proposed to underlie its cardiovascular benefit.1,2
Dosing & protocol.
Take with or at the end of a meal; absorption of the ester is improved by dietary fat and food helps ensure adequate exposure. Capsules must be swallowed whole.3
Full safety detail.
Side effects
- Musculoskeletal pain (arthralgia)
- Peripheral edema
- Constipation
- Gout
- Atrial fibrillation or atrial flutter (increased incidence, particularly with prior history)
- Increased bleeding risk, especially when combined with antiplatelet or anticoagulant therapy
- Eructation (belching) and a fishy aftertaste
- Nausea or other gastrointestinal upset
Contraindications
- Known hypersensitivity to icosapent ethyl or any component of the product1,2
- Use with caution in patients with known hypersensitivity to fish or shellfish, as safety has not been fully established
- Caution in patients with history of atrial fibrillation or atrial flutter given increased arrhythmia risk1,3
- Caution in patients at increased risk of bleeding or receiving anticoagulant, antiplatelet, or other bleeding-risk supplements1,3
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
2- 1Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT)PMIDBhatt DL, Steg PG, Miller M, et al. · New England Journal of Medicine · 2019
Among 8,179 statin-treated patients, icosapent ethyl reduced the primary composite endpoint by approximately 25% versus placebo, with a modest increase in atrial fibrillation and a nonsignificant trend toward more serious bleeding.
- 2Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) in Patients with Very High Triglyceride Levels (MARINE)PMIDBays HE, Ballantyne CM, Kastelein JJ, et al. · American Journal of Cardiology · 2011
In patients with triglycerides 500 mg/dL or higher, icosapent ethyl 4 g/day significantly reduced triglycerides by about 33% without increasing LDL cholesterol relative to placebo.
Reference material
1- 3Vascepa (icosapent ethyl) Prescribing InformationAmarin Pharma, Inc. · US FDA Label · 2019
Labeling specifies a 4 g/day dose taken with food, indications for severe hypertriglyceridemia and cardiovascular risk reduction, and warnings regarding atrial fibrillation/flutter and bleeding.
Common questions.
Quick answers about Icosapent Ethyl, drawn from the data on this page.
What is Icosapent Ethyl?
Icosapent ethyl is a highly purified ethyl ester of eicosapentaenoic acid (EPA) prescribed to lower very high triglycerides and to reduce the risk of cardiovascular events in selected patients already on statin therapy. Unlike combination fish oil products, it contains only EPA and no docosahexaenoic acid (DHA), which avoids the LDL-cholesterol increases sometimes seen with DHA-containing preparations. It is taken as oral capsules with food.
What is Icosapent Ethyl used for?
Commonly cited benefits of Icosapent Ethyl include: Adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglycerides at or above 500 mg/dL); Reduction of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, unstable angina) in statin-treated adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors. NutriStack rates the overall evidence as strong.
What is a typical dose of Icosapent Ethyl?
A typical adult dose of Icosapent Ethyl is 4 grams per day taken orally, given as either two 1-gram capsules twice daily or four 0.5-gram capsules twice daily, with food. The commonly recommended form is Oral soft gelatin or liquid-filled capsule (0.5 g and 1 g strengths); swallow whole, do not crush, dissolve, or chew. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Icosapent Ethyl?
Reported side effects include musculoskeletal pain (arthralgia), peripheral edema, constipation, gout, atrial fibrillation or atrial flutter (increased incidence, particularly with prior history), increased bleeding risk, especially when combined with antiplatelet or anticoagulant therapy. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Icosapent Ethyl?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Icosapent Ethyl in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.